YUCAIPA, Calif., Sept. 7, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT) announced today that it has signed a definitive sales agreement with Healthstar Associates Incorporated to expand distribution throughout the mid-west U.S. ( http://healthstarassociates.com/ ).
Healthstar Associates is a Regional Medical Sales and Marketing company headquartered in Lincolnwood, Illinois and doing business for almost 20 years. Healthstar Associates has a long history as a responsive, knowledgeable manufacturers' representative in the Midwest and Canada; functioning as a sales and marketing force for a wide range of medical manufacturers. Healthstar will target the respiratory markets including already established sales channels with hospitals, DME's, Medical Suppliers, Nursing Facilities, Assisted Living and Home Care Providers.
"Unlike a typical U.S. or Canadian firm that specializes in a narrow segment of the healthcare market, says Barry Petrigala, President and Founder, "we've proven our ability to effectively reach a broader spectrum of markets which include: Hospitals, Home Healthcare, Nursing homes, Occupational health, Physical therapists, Fire/safety, Physicians, Rehabilitation, Chiropractors and Dental markets."
"We are very pleased to welcome the Healthstar team to Ingen Technologies," stated Scott R. Sand, CEO and Chairman of the Board of Ingen Technologies. "The new sales contract with Healthstar Associates is another significant step in the continued evolution of our product sales and product recognition."
Over the past several months, the company has obtained an ISO certification to sell internationally, through its partnership with the KGMA who has registered Ingen with the CCR to sell to the U.S. Department of Defense, signed contracts with MediGroup Physician Services, and has attended several conferences to drum up business in all of its segments. As a result, Ingen has projected that its total 2010 sales will reach $11 million this year, supported by growth in these government, commercial and international export market opportunities.
Investors can review our current fact sheet at the following link:
http://www.ingen-tech.com/PDFbin/FactSheet.pdf
About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 Billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.
CONTACT: Ingen Technologies, Inc. Jeff Morgan 909-790-7180 info@ingen-tech.com www.ingen-tech.com
